Tawata M, Miwa I, Tsuchiya K, Ozawa M, Shindo H, Wakasugi M, Onaya T
Third Department of Internal Medicine, University of Yamanashi Medical School, Japan.
Arzneimittelforschung. 1995 Jun;45(6):704-8.
The efficacy of pravastatin (CAS 81131-70-6) on serum lipid levels in 91 type 2 diabetic patients with mean glycosylated hemoglobin of 8.5% was investigated up to 12 weeks. Oral administration of 10 to 20 mg/d of pravastatin significantly decreased total cholesterol by 18.4 +/- 1.5% after 4 weeks. When analyzed separately in type IIa and IIb hyperlipidemia, the reduction of total cholesterol by pravastatin was more prominent in the former. Low-density lipoprotein cholesterol were also significantly decreased 22.2 +/- 2.7% after 4 weeks. The effect of pravastatin in reducing triglyceride was more prominent in patients with higher triglyceride compared to those with lower triglyceride before the administration of the drug. High-density lipoprotein cholesterol showed a slight but significant increase by 4.2 +/- 1.9% after 4 weeks. Among the apolipoproteins examined, apolipoprotein B was significantly decreased after 4 weeks. Atherogenic index and apolipoprotein B/apolipoprotein A-I ratio were also significantly decreased after 4 weeks. The efficacy of pravastatin was also observed after 12 weeks to the same extent as after 4 weeks. No major side effects or abnormalities of laboratory parameters have been observed. These data lead to the conclusion that pravastatin is useful for the treatment of hyperlipidemia in type 2 diabetic patients with poor glycemic control without major adverse effects.
对91例糖化血红蛋白平均为8.5%的2型糖尿病患者，研究了普伐他汀（CAS 81131-70-6）对血脂水平的影响，为期12周。口服10至20mg/d的普伐他汀4周后，总胆固醇显著降低18.4±1.5%。在IIa型和IIb型高脂血症患者中分别分析时，普伐他汀对总胆固醇的降低在前一种类型中更为显著。4周后，低密度脂蛋白胆固醇也显著降低22.2±2.7%。与用药前甘油三酯水平较低的患者相比，普伐他汀对甘油三酯水平较高的患者降低甘油三酯的效果更显著。4周后，高密度脂蛋白胆固醇略有但显著升高4.2±1.9%。在所检测的载脂蛋白中，载脂蛋白B在4周后显著降低。致动脉粥样硬化指数和载脂蛋白B/载脂蛋白A-I比值在4周后也显著降低。12周后观察到普伐他汀的疗效与4周后相同。未观察到重大副作用或实验室参数异常。这些数据得出结论，普伐他汀对血糖控制不佳的2型糖尿病患者的高脂血症治疗有效，且无重大不良反应。
